ZYNLONTA® (loncastuximab tesirine-lpyl), the First-and-Only CD19-
Targeted ADC, for the Treatment of Adults With R/R DLBCL After 2 or
More Lines of Systemic Therapy
Presenter:
Kayla Wilson, APRN
Nurse Practitioner
Norton Cancer Institute
Date: 6/17/2026 at 6:00 PM Central
Location:
Five West
1991 Commerce Dr NW
Rochester, Minnesota 55901
RSVP:
Allison Passolt
allison.passolt@adctherapeutics.com
952-240-9153